Mountain Lake Investment Management LLC Purchases Shares of 20,600 United Therapeutics Co. (UTHR)

Mountain Lake Investment Management LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the first quarter, HoldingsChannel reports. The firm purchased 20,600 shares of the biotechnology company’s stock, valued at approximately $2,315,000. United Therapeutics comprises 1.2% of Mountain Lake Investment Management LLC’s portfolio, making the stock its 15th biggest holding.

A number of other large investors also recently made changes to their positions in UTHR. Guggenheim Capital LLC grew its holdings in shares of United Therapeutics by 2.7% during the first quarter. Guggenheim Capital LLC now owns 106,049 shares of the biotechnology company’s stock worth $11,916,000 after purchasing an additional 2,818 shares during the last quarter. Element Capital Management LLC bought a new stake in shares of United Therapeutics during the first quarter worth $2,367,000. A.R.T. Advisors LLC grew its holdings in shares of United Therapeutics by 30.1% during the first quarter. A.R.T. Advisors LLC now owns 19,457 shares of the biotechnology company’s stock worth $2,186,000 after purchasing an additional 4,503 shares during the last quarter. Achmea Investment Management B.V. grew its holdings in shares of United Therapeutics by 47.7% during the first quarter. Achmea Investment Management B.V. now owns 17,242 shares of the biotechnology company’s stock worth $1,934,000 after purchasing an additional 5,567 shares during the last quarter. Finally, UBS Group AG grew its holdings in shares of United Therapeutics by 718.7% during the first quarter. UBS Group AG now owns 58,201 shares of the biotechnology company’s stock worth $6,540,000 after purchasing an additional 51,092 shares during the last quarter. Hedge funds and other institutional investors own 99.24% of the company’s stock.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 43,025 shares of the stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $111.11, for a total value of $4,780,507.75. Following the transaction, the chief executive officer now owns 21,652 shares of the company’s stock, valued at $2,405,753.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Judy D. Olian sold 600 shares of the stock in a transaction dated Tuesday, June 12th. The shares were sold at an average price of $112.38, for a total value of $67,428.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 153,134 shares of company stock worth $17,152,504. 8.20% of the stock is owned by company insiders.

United Therapeutics stock opened at $112.62 on Thursday. The stock has a market capitalization of $4.90 billion, a P/E ratio of 10.34, a PEG ratio of 28.77 and a beta of 1.32. United Therapeutics Co. has a 12-month low of $100.57 and a 12-month high of $152.55. The company has a current ratio of 5.13, a quick ratio of 4.81 and a debt-to-equity ratio of 0.11.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported $5.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.62 by $1.95. The business had revenue of $389.20 million for the quarter, compared to analysts’ expectations of $393.96 million. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business earned $3.61 earnings per share. equities analysts predict that United Therapeutics Co. will post 13.04 earnings per share for the current fiscal year.

UTHR has been the topic of several research analyst reports. BidaskClub cut United Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 1st. Credit Suisse Group decreased their target price on United Therapeutics from $108.00 to $104.00 and set a “neutral” rating on the stock in a report on Thursday, May 3rd. Barclays restated an “underweight” rating and set a $105.00 target price (down previously from $115.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, ValuEngine cut United Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $134.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply